Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GH Research ( (GHRS) ) has issued an update.
GH Research PLC announced the presentation of data from its GH001-BD-202 clinical trial at the International Society for Bipolar Disorders Annual Meeting held from September 17-19, 2025, in Chiba, Japan. The trial investigated the safety and antidepressant effects of GH001 in patients with Bipolar II Disorder experiencing a major depressive episode. The results showed a significant reduction in depressive symptoms, with a 52.5% decrease in the Montgomery–Åsberg Depression Rating Scale total score by Day 8, indicating promising potential for GH001 as a treatment option.
The most recent analyst rating on (GHRS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC operates in the pharmaceutical industry, focusing on developing innovative treatments for psychiatric disorders. The company is known for its work on psychoactive molecules, particularly its synthetic form of mebufotenin, GH001, which is designed for pulmonary inhalation to treat depressive episodes.
Average Trading Volume: 271,720
Technical Sentiment Signal: Buy
Current Market Cap: $874M
Learn more about GHRS stock on TipRanks’ Stock Analysis page.